Alan Chanin
Internal Medicine · Chester, NJNPI 1174517916
Payments from drug & device makers
Across 150 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$284
- Amgen$262
- Lilly USA, LLC$243
- Boehringer Ingelheim$150
- Pfizer$148
- AstraZeneca$128
- plus $827 from 19 others
What the payments were for
- Food & beverage$2,041100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $284 |
| Amgen | 21 | $262 |
| Lilly USA, LLC | 18 | $243 |
| Boehringer Ingelheim | 11 | $150 |
| Pfizer | 11 | $148 |
| AstraZeneca(2 entities) | 9 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Johnson & Johnson | 6 | $89 |
| Merck | 6 | $80 |
| Kowa Pharmaceuticals America, Inc. | 6 | $74 |
| Esperion Therapeutics, Inc. | 5 | $72 |
| Bayer | 4 | $67 |
| Abbott | 4 | $61 |
| AbbVie(2 entities) | 4 | $53 |
| Amarin Pharma, Inc. | 2 | $30 |
| GSK | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Seqirus USA Inc | 2 | $26 |
| Bausch Health US, LLC | 2 | $26 |
| Althera Pharmaceuticals LLC | 2 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$2,041 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $15,515 |
| Atorvastatin Calcium | 128 | $1,674 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 17 | $1,099 |
| Rosuvastatin Calcium | 64 | $991 |
| Valsartan | 13 | $926 |
| Levothyroxine Sodium | 73 | $844 |
| SynthroidLevothyroxine Sodium | 14 | $649 |
| Ezetimibe | 15 | $629 |
| Metoprolol Succinate | 44 | $588 |
| Montelukast Sodium | 20 | $487 |
| Pantoprazole Sodium | 29 | $416 |
| Metformin Hcl ErMetformin Hcl | 26 | $399 |
| Simvastatin | 21 | $374 |
| Amlodipine Besylate | 45 | $373 |
| Metformin Hcl | 20 | $326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $150 | $15,51512 claims |
| AbbVieSynthroid | $53 | $64914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Chester
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.